Drug name - Otiprio
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9603796 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(6 years from now) | |
| CN102099013A | ALK ABELLO | Controlled-Release Apoptosis Modulating Compositions And Methods For The Treatment Of Otic Disorders |
Apr, 2013
(9 years ago) | |
| CN102112111A | ALK ABELLO | Controlled Release Auris Sensory Cell Modulator Compositions And Methods For The Treatment Of Otic Disorders |
Feb, 2017
(5 years ago) | |
| CN102112112A | ALK ABELLO | Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders |
Mar, 2017
(5 years ago) | |
| CN104940126A | ALK ABELLO | Control Release Type Ear Structure Adjusting And Congenital Immune System Adjusting Composition, Device And Method For Treating Ear Disease |
Aug, 2018
(4 years ago) | |
| CN102105133B | ALK ABELLO | Control-Release-Type Ear Structure Regulation And Congenital Immune System Regulating Composition And Method For Treating Otic Disorders |
Jul, 2019
(3 years ago) | |
| CN102105133A | ALK ABELLO | Controlled-Release Otic Structure Modulating And Innate Immune System Modulating Compositions And Methods For The Treatment Of Otic Disorders |
Jul, 2019
(3 years ago) | |
| CN102014957A | ALK ABELLO | Auris Formulations For Treating Otic Diseases And Conditions |
Apr, 2021
(1 year, 5 months ago) | |
| CN102014957B | ALK ABELLO | For Otic Formulations For Treating Otic Diseases And Conditions |
Apr, 2021
(1 year, 5 months ago) | |
| CN103417472A | ALK ABELLO | A Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders |
Apr, 2022
(5 months ago) | |
| CN103417472B | ALK ABELLO | A Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders |
Apr, 2022
(5 months ago) | |
| CN102026623A | ALK ABELLO | Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders |
May, 2029
(6 years from now) | |
| CN102026623B | ALK ABELLO | Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders |
May, 2029
(6 years from now) | |
| CN104352429B | ALK ABELLO | For Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders |
Jul, 2029
(6 years from now) | |
| CN104352429A | ALK ABELLO | Controlled Release Antimicrobial Composition And Method For Treating Ear Part Condition |
Jul, 2029
(6 years from now) | |
| EP2303227A4 | ALK ABELLO | Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders |
May, 2029
(6 years from now) | |
| EP2303227A2 | ALK ABELLO | Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders |
May, 2029
(6 years from now) | |
| EP2303227B1 | ALK ABELLO | Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders |
May, 2029
(6 years from now) | |
| EP2299979A4 | ALK ABELLO | Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders |
Jul, 2029
(6 years from now) | |
| EP2299979B1 | ALK ABELLO | Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders |
Jul, 2029
(6 years from now) | |
| EP2299979A2 | ALK ABELLO | Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders |
Jul, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9205048 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(6 years from now) | |
| US9233068 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders |
Dec, 2029
(7 years from now) | |
| US8318817 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2030
(7 years from now) | |
| US9220796 | ALK ABELLO | Sterilization of ciprofloxacin composition |
Jul, 2035
(12 years from now) | |
| US11040004 | ALK ABELLO | Otic gel formulations for treating otitis externa |
Nov, 2037
(15 years from now) | |
Drugs and Companies using CIPROFLOXACIN ingredient
Treatment: Treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement; Treatment of otic infection or inflammation; The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus
Dosage: INJECTABLE, SUSPENSION;OTIC
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 6% (60MG/ML) | INJECTABLE, SUSPENSION;OTIC | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.